Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma

Bibliography

• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55(2):74-108
   PubMed Web of Science ®Google Scholar
• Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist 2006;11(7):790-800
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378-90
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10(1):25-34
   Google Scholar
• Wilhelm SM, Carter C, Tang L, BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64(19):7099-109
   PubMed Web of Science ®Google Scholar
• Liu L, Cao Y, Chen C, Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006;66(24):11851-8
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Schwartz L, Ricci S, Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24(26):4293-300
   Google Scholar
• Pinter M, Sieghart W, Graziadei I, Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 2009;14(1):70-6
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Amadori D, Santoro A, Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis? J Clin Oncol 2008;26(20 Suppl): abstract 4518
   Google Scholar
• Miller AA, Murry DJ, Owzar K, Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol 2009;27(11):1800-5
   PubMed Web of Science ®Google Scholar
• Zhu AX, Clark JW. Commentary: sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy. Oncologist 2009;14(1):67-9
   PubMed Web of Science ®Google Scholar
• Llovet JM, Di Bisceglie AM, Bruix J, Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100(10):698-711
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Johnson P, Knox J, Final results from a phase II (PhII), randomized, double-blind study of sorafenib plus doxorubicin (S+D) versus placebo plus doxorubicin (P+D) in patients (pts) with advanced hepatocellular carcinoma (AHCC). [abstract 128]. 2008 Gastrointestinal Cancers Symposium; Orlando, FL, USA
   Google Scholar
• Martinelli E, Troiani T, Laus G, Synergistic antitumor activity of the combination of the multitargeted tyrosine kinase inhibitor sorafenib and of EGFR inhibitors in human colon and lung cancer cell lines. Eur J Cancer 2006;4:123
   Web of Science ®Google Scholar
• Duran I, Hotte SJ, Hirte H, Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. Clin Cancer Res 2007;13(16):4849-57
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Troiani T, Bianco R, Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy. Ann Oncol 2006;17(Suppl 7):vii109-14
   PubMed Web of Science ®Google Scholar
• Philip PA, Mahoney MR, Allmer C, Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005;23(27):6657-63
   PubMed Web of Science ®Google Scholar
• Messerini L, Novelli L, Comin CE. Microvessel density and clinicopathological characteristics in hepatitis C virus and hepatitis B virus related hepatocellular carcinoma. J Clin Pathol 2004;57(8):867-71
   PubMed Web of Science ®Google Scholar
• Miura H, Miyazaki T, Kuroda M, Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J Hepatol 1997;27(5):854-61
   PubMed Web of Science ®Google Scholar
• Yamaguchi R, Yano H, Iemura A, Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 1998;28(1):68-77
   PubMed Web of Science ®Google Scholar
• Yamaguchi R, Yano H, Nakashima Y, Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues. Oncol Rep 2000;7(4):725-9
   PubMed Web of Science ®Google Scholar
• Chao Y, Li CP, Chau GY, Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol 2003;10(4):355-62
   PubMed Web of Science ®Google Scholar
• Jeng KS, Sheen IS, Wang YC, Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: a prospective study. World J Gastroenterol 2004;10(5):643-8
   PubMed Web of Science ®Google Scholar
• Poon RT, Ho JW, Tong CS, Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 2004;91(10):1354-60
   PubMed Web of Science ®Google Scholar
• Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005;315(3):971-9
   PubMed Web of Science ®Google Scholar
• Mendel DB, Laird AD, Xin X, In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9(1):327-37
   PubMed Web of Science ®Google Scholar
• Pawson T. Regulation and targets of receptor tyrosine kinases. Eur J Cancer 2002;38(Suppl 5):S3-10
   PubMed Web of Science ®Google Scholar
• Faivre S, Raymond E, Boucher E, Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 2009;10(8):794-800
   PubMed Web of Science ®Google Scholar
• Hoda D, Catherine C, Strosberg J, Phase II study of sunitinib malate in adult pts (pts) with metastatic or surgically unresectable hepatocellular carcinoma (HCC) [abstract 128]. 2008 Gastrointestinal Cancers Symposium; Orlando, FL, USA
   Google Scholar
• Koeberle D, Montemurro M, Samaras P, Continuous sunitinib treatment in patients with unresectable hepatocellular carcinoma (HCC): a multicenter phase II trial (SAKK 77/06 and SASL 23). J Clin Oncol 2009;27(15S): abstract 4591
   PubMed Web of Science ®Google Scholar
• Zhu AX, Sahani DV, Duda DG, Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009;27(18):3027-35
   PubMed Web of Science ®Google Scholar
• Huynh H, Ngo VC, Fargnoli J, Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 2008;14(19):6146-53
   PubMed Web of Science ®Google Scholar
• Raoul JL, Finn RS, Kang YK, An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC). J Clin Oncol 2009;27(15S): abstract 4577
   Google Scholar
• Toh H, Chen P, Carr BI, A phase II study of ABT-869 in hepatocellular carcinoma (HCC): Interim analysis. J Clin Oncol 2009;27(15s): abstract 4581
   Google Scholar
• Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7(9):987-9
   PubMed Web of Science ®Google Scholar
• Willett CG, Boucher Y, di Tomaso E, Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10(2):145-7
   PubMed Web of Science ®Google Scholar
• Siegel AB, Cohen EI, Ocean A, Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008;26(18):2992-8
   PubMed Web of Science ®Google Scholar
• Malka D, Dromain C, Farace F, Bevacizumab in patients (pts) with advanced hepatocellular carcinoma (HCC): preliminary results of a phase II study with circulating endothelial cell (CEC) monitoring. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S):4570
   Google Scholar
• Zhu AX, Blaszkowsky LS, Ryan DP, Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24(12):1898-903
   PubMed Web of Science ®Google Scholar
• Sun W, Haller DG, Mykulowycz K, Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): a phase II study. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S):4574
   Google Scholar
• Hsu C, Yang T, Hsu C, Modified-dose capecitabine + bevacizumab for the treatment of advanced/metastatic hepatocellular carcinoma (HCC): a phase II, single-arm study. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S):15190
   Google Scholar
• Thomas MB, Morris JS, Chadha R, Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009;27(6):843-50
   PubMed Web of Science ®Google Scholar
• Wedge SR, Kendrew J, Hennequin LF, AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005;65(10):4389-400
   PubMed Web of Science ®Google Scholar
• Alberts SR, Morlan BW, Kim GP, NCCTG phase II trial (N044J) of AZD2171 for patients with hepatocellular carcinoma (HCC)–Interim review of toxicity [abstract No: 186]. 2007 Gastrointestinal Cancers Symposium; Orlando, FL, USA
   Google Scholar
• Wood JM. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy. Medicina 2000;60(Suppl 2):41-7
   PubMed Web of Science ®Google Scholar
• Drevs J, Muller-Driver R, Wittig C, PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res 2002;62(14):4015-22
   PubMed Web of Science ®Google Scholar
• Koch I, Baron A, Roberts S, Influence of hepatic dysfunction on safety, tolerability, and pharmacokinetics (PK) of PTK787/ZK 222584 in patients (Pts) with unresectable hepatocellular carcinoma (HCC). 2005 ASCO Annual Meeting Proceedings Part I of II. J Clin Oncol 2005;23(16S):4134
   Google Scholar
• Yau CC, Chen PJ, Curtis CM, A phase I study of pazopanib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2009;27(15S): abstract 3561
   Google Scholar
• Carlin CR, Simon D, Mattison J, Knowles BB. Expression and biosynthetic variation of the epidermal growth factor receptor in human hepatocellular carcinoma-derived cell lines. Mol Cell Biol 1988;8(1):25-34
   PubMed Web of Science ®Google Scholar
• Harada K, Shiota G, Kawasaki H. Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma. Liver 1999;19(4):318-25
   PubMedGoogle Scholar
• Ito Y, Takeda T, Higashiyama S, Expression of heparin binding epidermal growth factor-like growth factor in hepatocellular carcinoma: an immunohistochemical study. Oncol Rep 2001;8(4):903-7
   PubMed Web of Science ®Google Scholar
• Kira S, Nakanishi T, Suemori S, Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinoma. Liver 1997;17(4):177-82
   PubMedGoogle Scholar
• Kiss A, Wang NJ, Xie JP, Thorgeirsson SS. Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas. Clin Cancer Res 1997;3(7):1059-66
   PubMed Web of Science ®Google Scholar
• Yeh YC, Tsai JF, Chuang LY, Elevation of transforming growth factor alpha and its relationship to the epidermal growth factor and alpha-fetoprotein levels in patients with hepatocellular carcinoma. Cancer Res 1987;47(3):896-901
   PubMed Web of Science ®Google Scholar
• Thomas MB, Chadha R, Glover K, Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007;110(5):1059-67
   Google Scholar
• O'Dwyer PJ, Giantonio BJ, Levy DE, Gefitinib in advanced unresectable hepatocellular carcinoma: results from the Eastern Cooperative Oncology Group's Study E1203. 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006;24(18S):4143
   PubMed Web of Science ®Google Scholar
• Ramanathan RK, Belani CP, Singh DA, A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol 2009;64(4):777-83
   PubMed Web of Science ®Google Scholar
• Bekaii-Saab T, Markowitz J, Prescott N, A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res 2009;15(18):5895-901
   PubMed Web of Science ®Google Scholar
• Zhu AX, Stuart K, Blaszkowsky LS, Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 2007;110(3):581-9
   PubMed Web of Science ®Google Scholar
• Gruenwald V, Wilkens L, Gebel M, A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: final results. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S):4598
   Google Scholar
• Louafi S, Boige V, Ducreux M, Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer 2007;109(7):1384-90
   PubMed Web of Science ®Google Scholar
• O'Neil BH, Bernard SA, Goldberg RM, Phase II study of oxaliplatin, capecitabine, and cetuximab in advanced hepatocellular carcinoma. J Clin Oncol 2008;26(20 Suppl): abstract 4604
   PubMed Web of Science ®Google Scholar
• Villanueva A, Chiang DY, Newell P, Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008;135(6):1972-83, 83 e1-11
   PubMed Web of Science ®Google Scholar
• Chen L, Shiah HS, Chen CY, Randomized, phase I, and pharmacokinetic (PK) study of RAD001, an mTOR inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2009;27(15S): abstract 4587
   Google Scholar
• Huynh H, Nguyen TT, Chow KH, Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol 2003;3:19
   PubMed Web of Science ®Google Scholar
• O'Neil BH, Williams-Goff LW, Kauh J, A phase II study of AZD6244 in advanced or metastatic hepatocellular carcinoma. J Clin Oncol 2009;27(Suppl): abstract 15574
   PubMedGoogle Scholar